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A B S T R A C T   
Curcumin is a bioactive ingredient found in the Rhizomes of Curcuma longa. Curcumin is well known for its 
chemopreventive and anti-cancer properties. Recent findings have demonstrated several pharmacological and 
biological impacts of curcumin, related to the control and the management of gastrointestinal cancers. Mecha-
nistically, curcumin exerts its biological impacts via antioxidant and anti-inflammatory effects through the 
interaction with various transcription factors and signaling molecules. Moreover, epigenetic modulators such as 
microRNAs (miRNAs) have been revealed as novel targets of curcumin. Curcumin was discovered to regulate the 
expression of numerous pathogenic miRNAs in gastric, colorectal, esophageal and liver cancers. The present 
systematic review was performed to identify miRNAs that are modulated by curcumin in gastrointestinal cancers.   
1. Introduction 
Malignant neoplasms originated from the gastrointestinal (GI) tract 
and related organs are the main indicator of cancer morbidity and 
mortality all over the world [1,2]. Despite recent advances in control, 
management and individualized therapies, clinical findings for the 
majority of GI are still unclear [3,4]. 
Recently high polyphenol herbs with multi-functional actions seem 
to be very interesting in the prevention and management of malig-
nancies [5]. Curcumin (1,7-bis(4-hidroxy-3-methoxyphenyl)-1,6-hep-
adiene-3,5-dione), is an important nontoxic [6] yellow pigment of 
Curcuma longa, which has several anti-oxidant and anti-inflammatory 
properties [7] (Fig. 1). curcumin is a diarylheptanoid, belonging to the 
group of curcuminoids, which are natural phenols responsible for tur-
meric’s yellow color [8]. It is demonstrated that curcumin has been used 
to manage a variety of oxidative stress-related conditions and chronic 
diseases [9]. Curcumin, has been shown to be a strong antitumor agent 
[10]. So far, there is lot of evidence demonstrated that curcumin has an 
apoptotic and anti-tumor function in cancer cells, although, it is known 
that it also suppresses metastatic spread and prevents cancer cell pro-
liferation too [11]. 
Curcumin exhibits its beneficial effects on inflammation and oxida-
tive stress in various ways; it was shown to suppress the generation of 
different type of cytokines, such as TNF-α and IL-1β [12]; curcumin has 
been shown to scavenge ROS through its original antioxidant function 
and increasing antioxidant response [13]; curcumin also has been shown 
to modulate several transcriptional and translational factors that affect 
oxidative stress and oxidant defense enzymes [14–16]. Recently it has 
been shown that curcumin may exert its effects through affecting several 
types of microRNAs (miRNAs) [17,18]. 
MiRNAs, a key component of the non-coding RNA family [19,20], 
play multiple cellular functions such as cell growth and proliferation, 
cell cycle, differentiation, programmed cell death (apoptosis), and tissue 
development [21–23]. MiRNA in humans and so many other living or-
ganisms has varying genomic backgrounds, which include intragenic 
and intergenic non-coding RNA sequences in introns or some situations 
within an exon of the gene [24]. Mature miRNA biogenesis begins with 
* Correspondence to: Colorectal Research Center, Rasoul-e-Akram Hospital, Sattarkhan Ave, Niyayesh St., Tehran, Iran. 
E-mail addresses: Sedaghat@sbmu.ac.ir (M. Sedaghat), aptabaiyan@gmail.com (S.P. Tabaeian), ana.pizarro@fvl.org.co (A.B. Pizarro), ghasedakg35@yahoo.com 
(Z. Rostami), agah.sh@iums.ac.ir (S. Agah).  
Contents lists available at ScienceDirect 
Biomedicine & Pharmacotherapy 
journal homepage: www.elsevier.com/locate/biopha 
https://doi.org/10.1016/j.biopha.2021.111849 
Received 19 March 2021; Received in revised form 8 June 2021; Accepted 24 June 2021   
Biomedicine & Pharmacotherapy 141 (2021) 111849
2
RNA polymerase II function of long non–protein sequence coding RNA 
primary transcripts, called precursor miRNAs [21,25]. These sequences 
are further modified by DROSHA and its linking partners (e.g., DGCR8) 
cause to primary miRNAs (pri-miRNA). Afterward, pri-miRNAs are 
moved into the cytoplasm through exportin 5; they intricate to DICER 
and RNA-induced silencing complex (RISC), which contains argonaute 
complexes. In cohesion with RISC, a leading strand helps to guide the 
mature miRNAs to the target mRNA, in consequence leading to down-
regulation of target genes (Fig. 2). MiRNA biogenesis process is a tightly 
regulated procedure. Demodulation of miRNAs caused by the change in 
the pathway proteins biogenesis, such as DROSHA, DICER, and AGO2 
could happen in cancer cells [26,27]. These changes could be as a 
consequence of either biogenesis faults under the impacts of hypoxia 
[28,29] or miRNA transcriptional alterations [30,31]. Despite biogen-
esis faults and systemic downregulation in miRNAs [26,29,32–34], 
several oncogenic miRNAs remarkably enhance in cancer cells [34–36]. 
Mechanisms by which the expression of oncogenic miRNAs increases in 
cancer cells are different and specific miRNA–dependent [37–39]. 
However, the effect of curcumin on cancers through miRNAs was eval-
uated before [40–42], but we want to focus on gastrointestinal cancers, 
so we summarized recent advances in understanding the complex 
interplay between miRNA regulations which is mediated by curcumin by 
a particular focus on gastrointestinal cancers. 
2. Search strategy 
A systematic electronic database search was conducted in Medline 
(http://www.ncbi.nlm.nih.gov/pubmed), Scopus (http://www.scopus. 
com) and Google Scholar (http://scholar.google.com) without any lan-
guage limitation, to find all published studies related to the impacts of 
curcumin on miRNAs. The search key terms included ["Curcumin OR 
Curcuma OR Curcuminoid OR Tumeric OR Zedoary zedoaria OR Longa 
OR Curcuma longa"] AND [Cancer OR malignancy OR Gastrointestinal 
Cancer OR esophageal cancer OR gastric cancer OR pancreatic cancer 
OR liver cancer OR small bowel cancer OR colon cancer OR rectal 
cancer] AND [MicroRNA OR MiRNA OR noun-coding RNA] in titles and 
abstracts. The search was conducted from inception to August 1, 2020. 
The primary database search yielded 255 records. After careful evalu-
ation of titles and abstracts, 20 articles were selected and assessed in full 
text. After excluding duplicate and non-original documents, 11 articles 
were found eligible for the final review. 
3. Effect of curcumin on oxidative stress through miRNAs 
Dietary polyphenolic ingredients, including curcumin, have been 
involved in several biologic functions such as differentiation, develop-
ment, proliferation, cellular stress, and oxidative stress signaling 
[43–45]. These pathways have been determined to be modulated by 
miRNAs [46,47]. Oxidative stress occurs when the amount of oxidant 
and ROS particles are greater than the potential of the antioxidant de-
fense system of the host [48]. Reactive oxygen species (ROS), including 
hydroxyl radicals, superoxide anions, and hydrogen peroxide (H2O2) are 
easily produced under oxidative stress circumstances [49,50]. It has 
been shown that curcumin efficiently protects cells against H2O2 
induced oxidative stress damage [51]. Curcumin neutralized the H2O2 
induced OS by reducing MDA concentration, upregulating gene 
expression of Mn-SOD, Cu/Zn-SOD, GPX-4 and GPX-1, and increasing 
CAT, SOD activity [52]. We found that curcumin alleviated H2O2 
induced oxidative stress, intestinal epithelial barrier injury and mito-
chondrial damage. 
Oxidative stress (OS) refers to the increased intracellular concen-
tration of ROS due to increasing oxidant factors or a decrease in the 
antioxidant defense system potential of the body [53]. ROS are 
by-products of aerobic metabolism substances that include the hydroxyl 
radicals (OH⋅), hydrogen peroxide (H2O2), and superoxide anion (O2–) 
Nomenclature 
STAT3 Signal transducer and activator of transcription 3 
AGO2 Argonaute RISC Catalytic Component 2 
Bcl-2 B-cell lymphoma 2 
BAX Bcl-2-associated X protein 
CDK4 Cyclin Dependent Kinase 4 
PTEN Phosphatase and tensin homolog 
Akt Protein kinase B 
mTOR mechanistic target of rapamycin 
PI3K Phosphoinositide 3-kinase 
MAPK Mitogen-activated protein kinase 
MDA Malondialdehyde 
SOD Superoxide dismutase 
GPx Glutathione peroxidase 
CAT Catalase 
CRC Colorectal cancer 
PDCD4 Programmed Cell Death 4 
CDF curcumin-difluorinated 
ROS reactive Oxygen Species 
ZBTB4 Zinc Finger And BTB Domain Containing 4 
ZBTB10 Zinc Finger And BTB Domain Containing 10 
HCC Hepatocellular cancer 
CD40 Cluster of differentiation 40 
SP1 Specificity protein 1 
KLF4 Kruppel-like factor 4 
PDGF platelet-derived growth factor 
C/EBPα CCAAT-enhancer-binding proteins 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B 
cells 
EZH2 Enhancer of zeste homolog 2 
SET8 DNA methyltransferase 
MTA1 metastasis-associated gene 1  
Fig. 1. Curcumin is a bright yellow chemical produced by Curcuma longa 
plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member 
of the ginger family, Zingiberaceae. Chemically, curcumin is a diarylheptanoid, 
belonging to the group of curcuminoids, which are natural phenols responsible 
for turmeric’s yellow color. 
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[54]. ROS overload is often related to the oxidative stress, which induces 
the pathology of various chronic and acute diseases by damaging lipids, 
proteins, and DNA [55,56]. 
4. Effect of curcumin on cell survival and apoptosis through 
miRNAs 
There is a growing of evidence proposing that various mechanisms 
are likely responsible for the multiple pharmacologic impacts of cur-
cumin on anti-tumor-related pathways [57]. One of the mechanisms by 
which curcumin shows its anti-tumor function is apoptosis. Curcumin 
causes apoptosis in several types of cancers via multiple processes. For 
example, it leads to apoptosis in prostate cancer cells through iron 
chelation [58]. In melanoma cancer cells, it has been shown that 
generating ROS is another way that curcumin causes apoptosis [59]. It is 
also demonstrated that curcumin treatment significantly increases the 
sensitivity of lung cancer cells to Paclitaxel and decreases cell survival of 
cancer cells. It has revealed that curcumin could decrease the gene 
expression of MTA1 gene by upregulation of microRNA-30c in 
Paclitaxel-resistant lung cancer cells [60]. Also it has been demonstrated 
that curcumin decreases cell survival of cancer cells through its effect on 
inhibition of growth factors such as IGF-1 and insulin [61,62]. Recent 
outcomes suggest that curcumin can modulate Jak/STAT, NF-κB, jun, 
extracellular signal pathways in apoptosis through the regulation of 
specific miRNAs [17,41]. 
5. Curcumin and gastrointestinal cancers 
As was mentioned above, curcumin possesses excellent anti-oxidant 
function. This pharmacological function is getting more attention in the 
field of gastrointestinal cancers [63]. In this field, for instance, colo-
rectal cancer (CRC) is represented as one of the leading cause of mor-
tality, even in developed communities. Diet and lifestyle changes are the 
main contributors to the development of CRC [64]. In recent years, 
attention towards consuming plant derived-natural ingredients in order 
to manage and treat gastrointestinal cancers has increased, and curcu-
min is one of these plant derived-natural compounds. We evaluated 
current evidence about the effect of curcumin on gastrointestinal can-
cers through its effects on miRNAs (Table 1). 
Fig. 2. MiRNA biogenesis and activity. The 
canonical miRNA biogenesis major pathway is 
Drosha- and Dicer-dependent. It begins with 
RNA Polymerase II-conducted transcription of 
miRNA genes. The pri-miRNA is metabolized in 
the nucleus by Drosha and DGCR8 to form pre- 
miRNA. The pre-miRNA is then exit from nu-
cleus into the cytoplasm by Exportin-5. In the 
cytoplasm, pre-miRNA is further modified by 
the RNase III enzyme, Dicer. Integration with 
Dicer cause to degradation of the anti-sense 
strand of the miRNA duplex. The cytoplasmic 
pri-miRNA has been affected by AGO2, how-
ever the exact mechanism of miRNA maturation 
through this pathway still not clearly under-
stood. Mature miRNA can function through 
three primary pathways: (1) destabilization and 
cleavage of target mRNA, (2) mRNA stabiliza-
tion, and (3) translational repression.   
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5.1. Gastric cancer 
Curcumin has several pharmacological activities such as antitumor, 
antioxidative, and so on. It has been shown that curcumin has a lipo-
philic structure that makes it possible for it to penetrate the cell mem-
brane easily and induce apoptosis [65,66]. These results demonstrated 
that curcumin administration inhibited the proliferation and induced 
cell apoptosis in gastric cancer cells. It has been shown that Curcumin 
suppressed the proliferation of gastric cancer cells, through upregulating 
of miR-34a [67]. Also, it has been demonstrated that the effect of cur-
cumin in the suppression of gastric cancer cell proliferation is performed 
through inhibiting the levels of CDK4, Bcl-2, suppressing the G0/G1-S 
phase of the cell cycle, and inhibiting cyclin D1 in gastric cancer cells. 
Cyclin D1 is one of the regulators of the cell cycle that regulate the 
transition of cells from G1 to S phase [68]. Previous studies have shown 
that all of these factors also can be modulated by miRNAs [69,70]. 
Curcumin has been demonstrated to have a pivotal role in sup-
pressing the progression of gastric cancer via different pathways, such as 
downregulation of β-catenin and STAT3 [71] and the Bcl/Bax-caspase 8, 
9-caspase 3 pathway [72,73]. However, the special and individual 
mechanisms of its suppression of gastric cancer are still not clearly un-
derstood. In terms of the future progression of practical management 
application involving curcumin, extensive additional investigates into 
the possible mechanisms are both urgent and crucial. It has been shown 
that, curcumin act as a suppressor in gastric cancer cells, and curcumin 
treatment causes to an enhanced expression of miR-33b and a decreased 
expression of X-linked inhibitor-of-apoptosis protein (XIAP). XIAP has 
been reported to potently suppress the enzymatic function of caspases at 
both the initiation phase (caspase-9) and the execution phase (caspase-3 
and caspase-7) of apoptosis [74]. These findings showed the possible 
role of curcumin in modulating apoptosis through miR-33b and XIAP in 
GC. 
Gastric cancer cells studies have also discovered that the expression 
of ingredients of the miR-21/PTEN/Akt pathway was interrupted by 
curcumin [75]. PI3K/Akt/mTOR is a typical pro-survival and 
anti-apoptotic cellular signal transduction pathway, which modulates 
and controls several physiology and pathophysiology functions, 
including cell survival, proliferation, and migration [76]. The Akt 
signaling pathway regularly plays an important role in the control and 
regulation of the growth and proliferation of gastric cancer cells [77]. 
Moreover, it has been shown that suppression of the Akt signaling 
cascade can remarkably increase the apoptosis of gastric cancer cells 
[78]. MiRNAs post-transcriptionally regulates gene expressions. Recent 
findings have demonstrated that miR-21 is usually upregulated and acts 
as an oncogene in different types of malignancies [79]. As one of the 
targets of miR-21, PTEN has been shown to dephosphorylate 
phosphatidylinositol-3,4,5-trisphosphate in cells and act as a tumor in-
hibitor through suppression of the Akt/protein kinase B signaling 
pathway. Previous investigation has shown that miR-21 is upregulated 
in gastric cancer cells and the miR-21/PTEN/Akt molecular pathway has 
a critical role in the development of gastric cancer [80]. It has been 
demonstrated that suppressors of miR-21 significantly inhibit migration, 
invasion, proliferation, and colony formation of gastric cancer cells [81]. 
A recent investigation in MGC-803 cells, indicated that curcumin 
administration suppressed miR-21 and p-Akt expression, while the re-
sults show that curcumin also can increase PTEN protein expression 
[75]. These results proposed that curcumin administration effectively 
suppressed the miR-21/PTEN/Akt molecular pathway. In addition, 
curcumin remarkably induced apoptosis and suppressed proliferation in 
MGC-803 cells. These findings indicate that curcumin exerts its 
anti-cancer impacts in gastric cancer by suppressing the 
miR-21/PTEN/Akt molecular pathway. 
MAPKs are signaling components that have critical roles in cell dif-
ferentiation, proliferation, migration and survival [82]. The function of 
MAPK pathway inherently increases in numerous malignancies, such as 
gastric cancer [83]. It has been shown that curcumin treatment can 
inhibit MAPK pathway [84]. There are several levels of biological 
cross-talking between the MAPK pathway and PI3K/AKT/mTOR 
pathway [85]. So, it seems that suppression of both pathways with 
curcumin might lead to a more efficient anti-tumor effect compared to 
the suppression effect on one of these pathways. 
5.2. Colorectal cancer 
Colorectal cancer (CRC) represents the third most diagnosed type of 
cancer worldwide with an increased incidence rate and high mortality. 
CRC initiation and development result from the cumulation over time of 
genetic alterations in colonic epithelium cells with epigenetic changes 
Table 1 
Effect of curcumin on various microRNAs in GI cancers.  
Cancer microRNAs Effect of 
curcumin 
Target gene/ transcription factora Biological function Ref 
Gastric miR-34a Up-regulation CDK4, Bcl-2 ↓Cell proliferation [68] 
miR-33b Up-regulation XIAP ↑Apoptosis [74] 
miR-21 Down-regulation PTEN/Akt ↑Apoptosis [76] 
miR-21 Down-regulation PI3K/Akt/mTOR ↓Cell survival, ↓proliferation, and 
↓migration 
[75] 
Colorectal miR-21 Down-regulation PI3K/Akt/mTOR ↓Cell survival, ↓proliferation, and 
↓migration 
[77] 
miR-27 Down-regulation Pdcd4 ↓Cell survival [101] 
miR-34 Up-regulation EMT ↓Chemoresistant [104] 
miR-20a, miR-27a, and miR- 
17 
Down-regulation ZBTB4, ZBTB10 ↓Cell growth [105] 
Hepatocellular miR-200a and miR-200b Up-regulation EMT ↓Metastasis, ↓chemotherapeutic 
resistance 
[110] 
miR-29a and miR-185 Up-regulation DNA (cytosine-5-)-methyltransferase 1, 3A 
and 3B 
↑DNA methylation [113] 
Pancratic miRNA-22 Up-regulation SP1, KLF4, PDGF, C/EBPα and NF-κB ↓Cell proliferation and migration [125] 
let-7 miRNAs Up-regulation EZH2 ↓Cell proliferation and migration [134–136] 
miR-200 Up-regulation EZH2 ↓Tumor development and metastasis [139,140] 
miR-7 Up-regulation SET8 ↑Apoptosis [142] 
Esophageal miR-21 Down-regulation Pdcd4, Bcl2 ↑Tumor suppression, ↑Apoptosis [152]  
a Abbreviations: Bcl-2: B-cell lymphoma 2, CDK4: Cyclin Dependent Kinase 4, PTEN: Phosphatase and tensin homolog, Akt: Protein kinase B, mTOR: mechanistic 
target of rapamycin, PI3K: Phosphoinositide 3-kinase, PDCD4: Programmed Cell Death 4, CDF: curcumin-difluorinated, ZBTB4: Zinc Finger And BTB Domain Con-
taining 4, ZBTB10: Zinc Finger And BTB Domain Containing 10, SP1: Specificity protein 1, KLF4: Kruppel-like factor 4, PDGF: platelet-derived growth factor, C/EBPα: 
CCAAT-enhancer-binding proteins, EZH2: Enhancer of zeste homolog 2, SET8: DNA methyltransferase 
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well-known as remarkable factors to cancer progression. CRC “epi-
genome” assessment showed that approximately all CRC have aber-
rantly methylated genes and altered miRNA expression [86]. 
CRC cells frequently resist the apoptotic process leading to the 
pathogenesis and development of neoplastic complications [87]. 
Resisting cells against death acquires different strategies to restrict 
apoptotic pathways. The basic mechanism by which malignant tumors 
resist against apoptosis process refers to an imbalance between 
pro-apoptotic and anti-apoptotic molecules, the restricted function of 
caspase, or defected cell lysis receptor signaling [88,89]. In addition, 
dysregulation of miRNA and their mRNA targets lead to the ini-
tiation/progression of colon carcinogenesis as well as invasion, angio-
genesis, and metastasis [90,91]. Michael et al. [92] reported a dramatic 
downregulation of miR-145 and miR-143 in CRC, suggesting a role of 
miRNAs in CRC pathogenesis. Other studies have demonstrated the 
downregulation of miR-21 and retrieve the expression of miR-34 family 
in CRC [93]. Therefore, miRNAs may have prognostic and diagnostic 
applications for CRC patients. MiRNAs might also show novel treatment 
targets for gene therapy in the management of CRC. 
Conventional oncologic treatments including chemotherapy, by 
activating proapoptotic mechanisms, have the potential to eliminate 
cancer cells [94]. Unfortunately, most anticancer drugs lead to signifi-
cant side effects on normal cells and tumor resistance [95]. In this 
context, the combination of natural or dietary agents and anticancer 
drugs is an emerging area of cancer research. 
Curcumin, as a bioactive component, induces apoptosis in CRC 
through both intrinsic and extrinsic pathways [96,97]. In CRC cells, the 
administration of curcumin leads to an up-regulation of pro-apoptotic 
components of the Bcl-2 family with the release of cytochrome-c from 
the mitochondria by down-regulation of the antiapoptotic protein Bcl-2 
and oligomerization of the Bax protein [98,99]. Furthermore, the 
modulation of miRNA expression by curcumin in cell lines has been 
reported as a mechanism promoting anticancer effects [100]. Several 
studies highlighted the inhibition of miR-21 and miR-27 expression, 
tumor growth, invasion, and metastasis of curcumin. Curcumin stabi-
lizes its tumor suppressor target Pdcd4 in CRC cells as well [101]. 
Likewise, curcumin-difluorinated (CDF), a curcumin analog with higher 
bioavailability, down-regulates miR-21 expression in chemo-resistant 
CRC cells via restoring PTEN levels and decreasing Akt phosphoryla-
tion [102]. Besides to miR-21, curcumin and CDF retrieve the expression 
of miR-34 family which has been lost in CRC partly via demethylation of 
the respective promoters [93,103]. Curcumin-mediated chemo-
sensitization to 5-FU also occurred by up-regulation of 
epithelial-mesenchymal transition (EMT)-suppressive miRNAs, 
including miR-34, further highlighting its potential therapeutic use as an 
adjunct in patients with chemoresistant advanced CRC [104]. In line 
with these findings, curcumin showed CRC growth inhibition by ROS 
induction and reduction of Sp family of transcription factors as well as 
their regulators (i.e., ZBTB4 and ZBTB10) through miR-20a, miR-27a, 
and miR-17 [105]. Therefore, curcumin is known to modulate the 
eradication of CRC cells, potentially exerting its anti-cancer effect by 
affecting various miRNA-mediated epigenetic mechanisms. 
5.3. Hepatocellular cancer 
Hepatocellular cancer (HCC) is a comparatively chemoresistant 
gastrointestinal cancer, and patients with HCC experience resistance to 
almost all chemotherapeutic agents [106]. However, there are several 
novel agents that have been reported in the management of HCC, such as 
curcumin. MiRNAs have a pivotal function in gene expression in healthy 
and malignant cells. The miR-200 family is found to be involved in 
suppressing EMT, which is the initial phase of metastasis [107,108]. 
However, miR-200 family was also well known to have a critical role in 
chemotherapeutic resistance [109]. It has been shown that curcumin 
treatment promotes apoptosis in HCC cells through upregulating of 
miR-200a or miR-200b expression [110]. 
The modulation of cancer-related gene expression by miRNAs 
through epigenetic regulation could be a notable aspect of miRNAs 
function [111]. MiRNAs can affect the epigenetic landscape of cells by 
modulating particular epigenetic regulators including DNA methyl-
transferases, histone deacetylases, and histone acetyltransferases [112]. 
It has been indicated that curcumin can affect some of these epigenetic 
factors through its effect on miRNAs. It has been revealed that curcumin 
treatment can cause overexpression of miR-29a and miR-185 and 
down-regulate the expression of DNA (cytosine-5-)-methyltransferase 1, 
3A, and 3B, and subsequently elevate the expression of maternally 
expressed gene 3 in HCC via DNA hypomethylation [113]. 
5.4. Pancreatic cancer 
Pancreatic cancer is determined as the 14th most prevalent cancer 
and the 7th cause of cancer death in the world [114]. Recent in-
vestigations suggest that miRNA expression alteration may be an 
important mechanism underlying the diagnosis, pathophysiology, and 
management of pancreatic cancer [115]. It is crucial to control growth 
factors in gastrointestinal complications[ 61]. In addition, it has been 
demonstrated previously that curcumin has strong growth-suppression 
and apoptotic impacts on pancreatic cancer in vitro and in vivo [116, 
117]. 
These impacts of curcumin may be conducted via any of the several 
ways that curcumin intervenes with cell signaling [118,119]. Micro-
array experiments demonstrated that curcumin treatment on pancreatic 
cancer cells up-regulated the expression of some miRNAs (such as 
miRNA-22) but down-regulated some others (such as miRNA199a) 
[120]. In addition, it has been shown that curcumin implements its 
impacts on the miR-590–3p/CD40 axis to perform a protective activity 
in damaged endothelial cells [121]. 
Changing the expression of miRNA-22 by transfecting its miRNA 
oligonucleotides modulated the expression of its downstream tran-
scriptional factors such as SP1 [122]. Mechanistically, it has been shown 
that miR-22 suppresses vascular smooth muscle cell proliferation and 
migration by reducing the transcriptional factor SP1 [123]. It has been 
approved that transcriptional factor SP1 increases proliferation of can-
cer cells through binding to the Kruppel-like factor 4 (KLF4) promoter 
which enhances platelet-derived growth factor (PDGF)-BB-stimulated 
cells [124]. In addition, SP1 encodes other transcriptional factors of the 
ETS subfamily such as PU.1, which can regulate the transcription of 
particular genes through interrelating with other transcriptional factors 
including C/EBPα or NF-κB [125]. These results indicate that curcumin 
can decrease the proliferation and migration of cancer cells through 
miR-22/SP1 axis. And also it demonstrates that curcumin can affect 
inflammatory markers through immunomodulatory effects [126]. The 
effect of curcumin on inflammatory markers related to the immune 
system such as TNF-α and IL-6 has been shown in previous studies [127, 
128]. 
In addition to the effect of curcumin on miRNAs related to tran-
scriptional factors, it has been demonstrated that curcumin can affect 
cancer cells through the impact on epigenetic factors [129]. The histone 
methyltransferase EZH2 is one of the main epigenetic modulators of cell 
proliferation, development, and cancer cells survival [130]. It has been 
reported that EZH2 expression is enhanced in several human cancers, 
such as highly aggressive pancreatic cancers[131]. Curcumin has been 
indicated that affects pancreatic cancer cells through modulating EZH2 
expression [132]. Furthermore, it has been shown that the let-7 miRNAs 
family activity as strong tumor inhibitors has been observed to be 
decreased in neoplasms, which causes increased expression of Ras and 
c-Myc in tumor cells [133]. Moreover, the downregulation of let-7 
family of microRNAs has been reported in pancreatic cancer [134, 
135]. There are several pieces of evidence which indicated that EZH2 
inactivation led to the increased let-7 expression, and thus curcumin 
treatment increases expression of let-7 miRNAs family, which can 
decrease EZH2 activity in pancreatic cancer cells and tumors [136]. 
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Several recent shreds of evidence also expressed that miR-200 acts as 
a strong tumor inhibitor, essentially by suppressing the adherence of 
epithelial-to-mesenchymal transition (EMT) phenotype in process of the 
progression and development of tumors [137,138]. It has been observed 
that miR-200 expression was decreased in many cancers such as 
pancreatic tumors, which is related to metastasis and tumor progression 
[139,140]. Recent studies also indicated that the suppression of EZH2 
causes an enhancement in the expression of miR-200 in pancreatic tu-
mors, which show that EZH2 may be responsible for the modulation of 
miR-200 and let-7 in cancer cells. In this regard, curcumin treatment 
could increase the expression of miR-200 and let-7, which would be 
greatly beneficial in suppressing tumor development and metastasis 
[136]. 
In addition, there several investigations demonstrated that miR-7 
could function as a tumor inhibitor gene in different types of human 
cancers [141]. It has been reported that miR-7 suppressed cancer cells’ 
metastasis and growth and also enhanced the vulnerability of 
drug-resistant tumors to chemotherapeutic agents [141]. Furthermore, 
curcumin treatment has been suggested to inhibit cancer cells growth, 
invasion, and development, and cause cell apoptosis, which is related to 
enhance gene expression of miR-7 which led to reduce in the expression 
of SET8, one of the main miR-7 target genes in pancreatic cancer cells 
[142]. 
5.5. Esophageal cancer 
Esophageal is one of the sixth main causes of cancer mortality in 
developed countries [143]. Esophageal cancer is usually diagnosed at 
the very end stages, with less than 10% of 5-year survival [144]. The 
high rate of morbidity, mortality, and low response rates of current 
treatment methods have led to investigations for less harmful comple-
mentary and alternative remedies. It has been reported that curcumin 
induces apoptosis and suppresses proliferation in esophageal cancer 
[145,146]. 
These previous studies have shown that curcumin treatment inhibits 
the development of esophageal tumor colonies, suppresses esophago-
sphere formation, alleviates cell cycle arrest and increases apoptosis and 
also suppresses miRNA expression, and modulates cancer cells inhibitor 
miRNA expression [147]. It has been demonstrated that several miRNAs 
upregulated remarkably and particularly miR-21 is up-regulated about 
12 fold in esophageal tumors [148]. It has been shown that miR-21 is 
overexpressed in several solid cancer cells and it is related to tumor 
development, low rate of survival, and decrease response to therapeutic 
agents [149,150]. Curcumin intervention was confirmed to significantly 
decrease miR-21 expression in several types of tumors and metastasis 
[101,151]. Recent findings in esophageal cancer cells indicated that 
multiple targets have been identified for miR-21. The miR-21 has been 
demonstrated to significantly decrease the expression of gene Pdcd4 
which functions as a strong tumor suppressor [152]. In addition, miR-21 
can suppress the apoptosis process in cancer cells by modulating Bcl2 
expression [153]. Eventually, miR-21 have the capability to suppress 
gemcitabine-induced cell apoptosis through the PTEN and PI-3 kinase 
pathway [154]. It has been determined that curcumin affects the gene 
expression of these mentioned factors in esophageal tumors through 
suppression of miR-21 [147]. 
6. Conclusion 
In conclusion, molecular mechanisms are underlying curcumin- 
mediated miRNA regulation in the carcinogenesis of gastrointestinal 
cancers. In this regard, this review provides mechanistic evidence that 
curcumin intervention can be effective in the management of gastroin-
testinal cancer through its effect on modulation of some oncogenic or 
suppressive miRNAs. 
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